Voyager Acquisition’s Redemption Wave Leaves SPAC in Precarious State Ahead of Merger

99.67% of shareholders redeemed, leaving just 82,685 public shares. Trust account shrinks to $885K, net income plummets, and stock down 21% in month.

The scale of the cash-out at Voyager Acquisition Corp. has all but vaporized its public float, creating a market dynamic that bears little relation to the company’s underlying fundamentals. Holders of roughly 25 million Class A shares — representing 99.67% of the class — exercised their redemption rights after the SPAC secured shareholder approval for its combination with Veraxa Biotech. That exodus leaves just 82,685 shares in public hands, a sliver that has sent annualized volatility soaring to 115.89%.

What little remains in the trust account underscores the financial strain. Only about $885,000 is left after the mass withdrawal, a pittance for a biotech shell planning to funnel cash into antibody-drug conjugate research. The quarterly figures paint an equally stark picture: net income for the three months ended March 31, 2026, collapsed to just $180,499 from approximately $2.43 million a year earlier. Higher general and administrative expenses tied to the merger preparations ate into the bottom line, and the shrinking trust fund means less interest income to offset those costs.

The delayed quarterly report only adds to the uncertainty. Management notified the SEC on Friday that it would need the five-calendar-day grace period to file the full 10-Q, citing the complexity of the redemptions and the pro-forma accounting required for the Veraxa deal. Investors now expect the document to land by the middle of the coming week, which should clarify the precise financial footing for the combined entity.

On the market, the stock closed Friday at $10.36, up 2.17% on the day. That small bounce did little to repair the broader damage: the shares are still down 17.84% for the week and roughly 21% over the past month. The 50-day moving average of $11.93 sits 13.15% above the current price, a technical reminder that even the occasional green session cannot mask the underlying caution.

Voyager’s leadership insists the merger with Veraxa Biotech is formally approved and only awaits final execution. Upon completion, the company expects to rebrand and trade under the ticker “VRXA” on the Nasdaq. The real question is whether the post-merger balance sheet can support the research pipeline without fresh capital. With less than $1 million in the trust, a capital injection appears all but inevitable. The next handelswoche — shortened by the quarterly filing deadline — will test whether the market is willing to look past the empty shell and focus on Veraxa’s prospects.